Integra Lifesciences Holdings CORP Schedule 13G passive stakes

Paradigm Capital Management, Inc. has amended its Schedule 13G filing to report beneficial ownership of 3,439,098 shares, representing 4.42% of Integra Lifesciences Holdings Corp.'s common stock as of March 31, 2026.

Vanguard Portfolio Management has reported beneficial ownership of 5.02% of Integra LifeSciences Holdings Corp. common stock as of June 30, 2026.

Paradigm Capital Management, Inc. has reported beneficial ownership of 5.2% of Integra Lifesciences Holdings Corp. common stock as of March 31, 2026.

The Vanguard Group filed an amended Schedule 13G, indicating a 0% beneficial ownership in Integra LifeSciences Holdings Corp following an internal realignment.

Fuller & Thaler Asset Management, Inc. has updated its beneficial ownership in Integra LifeSciences Holdings Corp., reporting a 4.67% stake as of December 31, 2025.

Invesco Ltd. has reported a 4.5% beneficial ownership stake in Integra LifeSciences Holdings Corp. as a passive institutional investor.

Morgan Stanley has reduced its beneficial ownership in Integra LifeSciences Holdings Corp. to 4.3%, falling below the 5% threshold.

BlackRock, Inc. has filed an amended Schedule 13G, reporting a beneficial ownership of 13.2% in Integra LifeSciences Holdings Corp. as of June 30, 2025.

Rubric Capital Management LP and David Rosen have disclosed a 9.46% beneficial ownership stake in Integra Lifesciences Holdings Corporation, holding over 7.3 million shares.

Rubric Capital Management LP and David Rosen have jointly disclosed a beneficial ownership of 6.01% in Integra Lifesciences Holdings Corporation, totaling 4,643,672 shares of common stock.

Invesco Ltd. has filed a Schedule 13G, reporting a 5.3% beneficial ownership stake in Integra LifeSciences Holdings Corp, totaling 4,111,700 shares of common stock.